162 related articles for article (PubMed ID: 22435072)
1. Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany.
Stroet A; Hemmelmann C; Starck M; Zettl U; Dörr J; Friedemann P; Flachenecker P; Fleischer V; Zipp F; Nückel H; Kieseier BC; Ziegler A; Gold R; Chan A
Ther Adv Neurol Disord; 2012 Mar; 5(2):75-9. PubMed ID: 22435072
[TBL] [Abstract][Full Text] [Related]
2. Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?
Ellis R; Boggild M
Mult Scler; 2009 Apr; 15(4):505-8. PubMed ID: 19251838
[TBL] [Abstract][Full Text] [Related]
3. Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients.
Voltz R; Starck M; Zingler V; Strupp M; Kolb HJ
Mult Scler; 2004 Aug; 10(4):472-4. PubMed ID: 15327049
[TBL] [Abstract][Full Text] [Related]
4. Mitoxantrone-related acute leukemia in MS: an open or closed book?
Chan A; Lo-Coco F
Neurology; 2013 Apr; 80(16):1529-33. PubMed ID: 23589639
[TBL] [Abstract][Full Text] [Related]
5. Therapy-related acute leukaemia with mitoxantrone: four years on, what is the risk and can it be limited?
Ellis R; Brown S; Boggild M
Mult Scler; 2015 Apr; 21(5):642-5. PubMed ID: 25013152
[TBL] [Abstract][Full Text] [Related]
6. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.
Pascual AM; Téllez N; Boscá I; Mallada J; Belenguer A; Abellán I; Sempere AP; Fernández P; Magraner MJ; Coret F; Sanz MA; Montalbán X; Casanova B
Mult Scler; 2009 Nov; 15(11):1303-10. PubMed ID: 19825889
[TBL] [Abstract][Full Text] [Related]
7. [Mitoxantrone-related acute leukemia by multiple sclerosis. Case report and practical approach by unclear cytopenia].
Meyer C; Ansorge N; Siglienti I; Salmen S; Stroet A; Nückel H; Dührsen U; Ritter PR; Schmidt WE; Gold R; Chan A
Nervenarzt; 2010 Dec; 81(12):1483-9. PubMed ID: 21079910
[TBL] [Abstract][Full Text] [Related]
8. Therapy-related acute leukemia in two patients with multiple sclerosis treated with Mitoxantrone.
Colovic N; Suvajdzic N; Kraguljac Kurtovic N; Djordjevic V; Dencic Fekete M; Drulovic J; Vidovic A; Tomin D
Biomed Pharmacother; 2012 Apr; 66(3):173-4. PubMed ID: 22440894
[TBL] [Abstract][Full Text] [Related]
9. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
10. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis.
Ghalie RG; Mauch E; Edan G; Hartung HP; Gonsette RE; Eisenmann S; Le Page E; Butine MD; De Goodkin DE
Mult Scler; 2002 Oct; 8(5):441-5. PubMed ID: 12356214
[TBL] [Abstract][Full Text] [Related]
11. Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS.
Brassat D; Recher C; Waubant E; Le Page E; Rigal-Huguet F; Laurent G; Edan G; Clanet M
Neurology; 2002 Sep; 59(6):954-5. PubMed ID: 12297591
[TBL] [Abstract][Full Text] [Related]
12. Long-term risk of leukaemia or cardiomyopathy after mitoxantrone therapy for multiple sclerosis.
Mulroy E; Joyce E; Scott J; Melling J; Goggin C; Mahon N; O'Rourke K; Lynch T
Eur Neurol; 2012; 67(1):45-7. PubMed ID: 22156316
[TBL] [Abstract][Full Text] [Related]
13. Acute myeloid leukaemia induced by mitoxantrone: case report.
Arruda WO; Montú MB; de Oliveira Mde S; Ramina R
Arq Neuropsiquiatr; 2005 Jun; 63(2A):327-9. PubMed ID: 16100984
[TBL] [Abstract][Full Text] [Related]
14. Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort study.
Buttmann M; Seuffert L; Mäder U; Toyka KV
Neurology; 2016 Jun; 86(23):2203-7. PubMed ID: 27170571
[TBL] [Abstract][Full Text] [Related]
15. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.
Ramtahal J; Jacob A; Das K; Boggild M
J Neurol; 2006 Sep; 253(9):1160-4. PubMed ID: 16990994
[TBL] [Abstract][Full Text] [Related]
16. Leukaemia due to mitoxantrone.
Prescrire Int; 2007 Aug; 16(90):153-6. PubMed ID: 17724842
[TBL] [Abstract][Full Text] [Related]
17. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone.
Martinelli V; Cocco E; Capra R; Salemi G; Gallo P; Capobianco M; Pesci I; Ghezzi A; Pozzilli C; Lugaresi A; Bellantonio P; Amato MP; Grimaldi LM; Trojano M; Mancardi GL; Bergamaschi R; Gasperini C; Rodegher M; Straffi L; Ponzio M; Comi G;
Neurology; 2011 Nov; 77(21):1887-95. PubMed ID: 22076543
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment risks in multiple sclerosis: risk knowledge and risk perception in a large cohort of mitoxantrone-treated patients.
Hofmann A; Stellmann JP; Kasper J; Ufer F; Elias WG; Pauly I; Repenthin J; Rosenkranz T; Weber T; Köpke S; Heesen C;
Mult Scler; 2013 Jun; 19(7):920-5. PubMed ID: 23037548
[TBL] [Abstract][Full Text] [Related]
19. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.
Krug U; Röllig C; Koschmieder A; Heinecke A; Sauerland MC; Schaich M; Thiede C; Kramer M; Braess J; Spiekermann K; Haferlach T; Haferlach C; Koschmieder S; Rohde C; Serve H; Wörmann B; Hiddemann W; Ehninger G; Berdel WE; Büchner T; Müller-Tidow C; ;
Lancet; 2010 Dec; 376(9757):2000-8. PubMed ID: 21131036
[TBL] [Abstract][Full Text] [Related]
20. Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Marriott JJ; Miyasaki JM; Gronseth G; O'Connor PW;
Neurology; 2010 May; 74(18):1463-70. PubMed ID: 20439849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
